XPhyto Therapeutics (XPHY.C) announced today that its Good Manufacturing Practice (GMP) mescaline synthesis program is on schedule with the completion of initial production batches. “With both its North…
Search Results for: XPHY.C – Page 2
XPhyto Therapeutics (XPHY.C) announced their partner Max Pharma GmbH will begin to sell XPhyto’s rapid point-of-care Covid-19 PCR test system (Covid-ID Lab) in Germany next week. The Covid-ID Lab…
XPhyto Therapeutics (XPHY.C), a bioscience accelerator in the life science industry, announced today that its drug formulation programs are advancing on schedule and continue to expand in scope. “Vektor…
XPhyto Therapeutics (XPHY.C) announced they are beginning a pilot project with their rapid Covid-19 PCR test (Covid-ID Lab) in a point-of-care (POC) setting in Germany. The Covid-ID Lab test…
XPhyto Therapeutics (XPHY.C) has delivered 2,000 of its rapid, 25-minute polymerase chain reaction (PCR) tests, COVID-ID Lab, to an established medical distributor in Israel for clinical evaluation for the…
The PCR test system demonstrated clinical accuracy in detecting SARS-CoV-2 RNA within 25 minutes, making it an ideal screening tool for international airports….
XPhyto Therapeutics (XPHY.C) and its exclusive German diagnostics development partner, 3a-diagnostics GmbH (3a), announced they have received approval for their point-of-care Covid-19 rapid RT-PCR test system (Covid-ID Lab) for…
XPhyto Therapeutics (XPHY.C) and its exclusive German diagnostic development partner, 3a-diagnostics GmbH (3a), have announced they received their EN ISO 13485 certification for their rapid point-of-care, SARS-CoV-2 RT-PCR Test…
XPhyto (XPHY.C) has successfully completed their corporate rebranding and launched a new website. “The company is excited to introduce a fresh look at such a pivotal point in our…
“PCR tests are used to directly detect the presence of an antigen, rather than the presence of the body’s immune response, or antibodies,” states Medical Device Network, “By detecting…